UAWJ246
UAWJ246 is a covalent reversible inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 0.045 μM and a Ki of 0.036 μM. UAWJ246 exhibits potent antiviral activity by inhibiting SARS-CoV-2 viral replication and shows low cytotoxicity. UAWJ246 can be used in research related to SARS-CoV-2 infection, such as studies on COVID-19[1][2].
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1429218-79-0
- Formel: C25H34N4O6
- Molecular Weight:486.57
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
SARS-CoV-2 main protease 0.045 μM (IC50) |
SARS-CoV-2 main protease 0.036 μM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero C1008 | EC50 |
4.61 μM
Compound: 60; UAWJ246
|
Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero E6 cells assessed as reduction in viral replication incubated for 3 days by viral plaque assay
Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero E6 cells assessed as reduction in viral replication incubated for 3 days by viral plaque assay
|
[PMID: 37244162] |
In Vitro
UAWJ246 (0.37-30 μM, 48 h) inhibits SARS-CoV-2 viral replication in Vero E6 cells in a dose-dependent manner[1].
UAWJ246 (3 days) inhibits the viral replication of SARS-CoV-2 in Vero E6 cells with an EC50 of 4.61 μM in the plaque assay[1].
UAWJ246 (5 days) shows low cytotoxicity in multiple cell lines with CC50s > 100 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Vero E6 cells
-
Concentration:0.37, 1.1, 3.3, 10, 30 μM
-
Incubation Time:48 h
-
Result:Inhibited the viral replication in a dose-response manner.
Showed an EC50 of 15.13 μM.
Chemical Information
-
CAS. Nr. 1429218-79-0
-
Molecular Weight 486.57
-
Formel C25H34N4O6
-
SMILES
[C@@H](C[C@H]1C(=O)NCC1)(NC([C@@H](NC(OCC2=CC=CC=C2)=O)CC(C)C)=O)C(C(NC3CC3)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Sacco MD, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Adv. 2020;6(50):eabe0751. Published 2020 Dec 9. [Content Brief]
[2]. La Monica G, et al. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives. J Med Chem. 2022;65(19):12500-12534. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
UAWJ246 Related Classifications
HY-180387 Related Classifications
Powered by Bioz